Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
You may also be interested in...
“Paper NDAs”
Pursuing Rx-to-OTC switches under section 505(b)(2) of Hatch/Waxman patent law is "potentially a very good avenue" for companies to use, Morgan Lewis lawyer Stephen Paul Mahinka says at Regulatory Affairs Professionals Society annual conference in Washington, D.C. Oct. 9. Both Wyeth and McNeil used 505(b)(2) application, or "paper NDA," approach to seek OTC approval for loratadine (Schering-Plough's Claritin) (1"The Tan Sheet" Feb. 4, 2002, p. 3). Mahinka expects "some response" from FDA in next several months on citizen petition filed by Pfizer and Pharmacia in 2001 requesting FDA disallow 505(b)(2) NDAs from relying on innovator's data...
“Paper NDAs”
Pursuing Rx-to-OTC switches under section 505(b)(2) of Hatch/Waxman patent law is "potentially a very good avenue" for companies to use, Morgan Lewis lawyer Stephen Paul Mahinka says at Regulatory Affairs Professionals Society annual conference in Washington, D.C. Oct. 9. Both Wyeth and McNeil used 505(b)(2) application, or "paper NDA," approach to seek OTC approval for loratadine (Schering-Plough's Claritin) (1"The Tan Sheet" Feb. 4, 2002, p. 3). Mahinka expects "some response" from FDA in next several months on citizen petition filed by Pfizer and Pharmacia in 2001 requesting FDA disallow 505(b)(2) NDAs from relying on innovator's data...
“Paper NDAs”
Pursuing Rx-to-OTC switches under section 505(b)(2) of Hatch/Waxman patent law is "potentially a very good avenue" for companies to use, Morgan Lewis lawyer Stephen Paul Mahinka says at Regulatory Affairs Professionals Society annual conference in Washington, D.C. Oct. 9. Both Wyeth and McNeil used 505(b)(2) application, or "paper NDA," approach to seek OTC approval for loratadine (Schering-Plough's Claritin) (1"The Tan Sheet" Feb. 4, 2002, p. 3). Mahinka expects "some response" from FDA in next several months on citizen petition filed by Pfizer and Pharmacia in 2001 requesting FDA disallow 505(b)(2) NDAs from relying on innovator's data...